Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Molloy

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Trials|January 16, 2019
Correction to: AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority TrialDavid S Lawrence, Nabila Youssouf, Síle F Molloy, et al.
Trials|November 25, 2018
AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority TrialDavid S Lawrence, Nabila Youssouf, Síle F Molloy, et al.
Open Forum Infectious Diseases|December 1, 2025
Epstein-Barr Virus Central Nervous System Infections and Mortality Risk in Patients Presenting With Suspected Meningitis: Results From the Botswana National Meningitis Survey and the Harare Meningitis Aetiology StudyJayne Ellis, James Milburn, Kebatshabile Ngoni, et al.
Journal of the International AIDS Society|June 6, 2025
Household economic impact of HIV-associated cryptococcal meningitis in five countries in Southern and Eastern AfricaDavid S Lawrence, Charles Muthoga, Jack Adams, et al.
The Lancet. Global Health|November 18, 2022
Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trialDavid S Lawrence, Charles Muthoga, David B Meya, et al.
The New England Journal of Medicine|March 15, 2018
Antifungal Combinations for Treatment of Cryptococcal Meningitis in AfricaSíle F Molloy, Cecilia Kanyama, Robert S Heyderman, et al.
BMJ Open|April 4, 2019
AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence studyPonego Lloyd Ponatshego, David Stephen Lawrence, Nabila Youssouf, et al.
The New England Journal of Medicine|March 23, 2022
Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal MeningitisJoseph N Jarvis, David S Lawrence, David B Meya, et al.
The Lancet. Infectious Diseases|October 23, 2018
Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countriesAngela Loyse, Jessica Burry, Jennifer Cohn, et al.
Elife|January 10, 2017
Characterisation of the opposing effects of G6PD deficiency on cerebral malaria and severe malarial anaemiaGeraldine M Clarke, Kirk Rockett, Katja Kivinen, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Trials|January 16, 2019
Correction to: AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority TrialDavid S Lawrence, Nabila Youssouf, Síle F Molloy, et al.
Trials|November 25, 2018
AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority TrialDavid S Lawrence, Nabila Youssouf, Síle F Molloy, et al.
Open Forum Infectious Diseases|December 1, 2025
Epstein-Barr Virus Central Nervous System Infections and Mortality Risk in Patients Presenting With Suspected Meningitis: Results From the Botswana National Meningitis Survey and the Harare Meningitis Aetiology StudyJayne Ellis, James Milburn, Kebatshabile Ngoni, et al.
Journal of the International AIDS Society|June 6, 2025
Household economic impact of HIV-associated cryptococcal meningitis in five countries in Southern and Eastern AfricaDavid S Lawrence, Charles Muthoga, Jack Adams, et al.
The Lancet. Global Health|November 18, 2022
Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trialDavid S Lawrence, Charles Muthoga, David B Meya, et al.
The New England Journal of Medicine|March 15, 2018
Antifungal Combinations for Treatment of Cryptococcal Meningitis in AfricaSíle F Molloy, Cecilia Kanyama, Robert S Heyderman, et al.
BMJ Open|April 4, 2019
AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence studyPonego Lloyd Ponatshego, David Stephen Lawrence, Nabila Youssouf, et al.
The New England Journal of Medicine|March 23, 2022
Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal MeningitisJoseph N Jarvis, David S Lawrence, David B Meya, et al.
The Lancet. Infectious Diseases|October 23, 2018
Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countriesAngela Loyse, Jessica Burry, Jennifer Cohn, et al.
Elife|January 10, 2017
Characterisation of the opposing effects of G6PD deficiency on cerebral malaria and severe malarial anaemiaGeraldine M Clarke, Kirk Rockett, Katja Kivinen, et al.
Pageof 7